Clinical trials: Immunity, Cellular
Sepsis, SIRS(Systemic Inflammatory Response Syndrome)
The Changes of CD4+T Lymphocyte Subsets in Septic Patients
The purpose of this study is to explore the value of CD4+T lymphocyte subsets in cell immunity in the patients with sepsis.There are immunoparalysis in septic patients,the important player is the change of CD4+T lymphocyte,this…
- Trial name
- NCT01494389
- Where
- China
- Sponsor
- Chinese PLA General Hospital
Hepatitis B
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Hepatitis B vaccine is a safe and effective vaccine used widely throughout the world. Because of this it is a useful vaccine in which to develop new methods for studying immune responses.
- Trial name
- NCT01821547
- Testing
- Hepatitis B vaccine
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Coronavirus, SARS-CoV-2 Infection
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
- Conditions
- Coronavirus, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT05633446
- Testing
- PepGNP-COVID19 (One vaccination), Water for injection (One vaccination), PepGNP-COVID19 (Two vaccinations)
- Where
- 2 sites in Philippines
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
Acute Myelogenous Leukemia
Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)
Dendritic cells vaccinations are increasingly used in order to develop antitumoral immune response. This will be a Phase 2 trial using autologous dendritic cells pulsed with leukemic apoptotic corpse in acute myelogenous leukemia…
- Trial name
- CD lam (NCT01146262)
- Testing
- cell therapy product, injection of the cell therapy product
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Nantes University Hospital
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Background: HIV stands for human immunodeficiency virus, which is the virus that causes AIDS. There is currently no licensed vaccine to prevent HIV infection.
- Trial name
- NCT03783130
- Testing
- VRC-HIVRGP096-00-VP, Alum Adjuvant
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Pancreatic Cancer
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for…
- Trial name
- NCT01417000
- Testing
- GVAX Pancreas, CRS-207, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Aduro Biotech, Inc.
Graft-Versus-Host Disease
Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease
This study is designed to collect longitudinal biological samples from patients after hematopoietic cell transplantation (HCT) cared for at multiple bone marrow transplant centers to validate biomarkers of both acute and chronic…
- Trial name
- NCT02194439
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Indiana University
Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
This phase II trial studies the immune response after stem cell transplant in human immunodeficiency virus (HIV)-positive patients with hematologic cancer (blood cancer).
- Trial name
- NCT00968630
- Testing
- Laboratory Biomarker Analysis, Leukapheresis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fred Hutchinson Cancer Center
Influenza
Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005
The objectives of the study are to assess the immunogenicity and safety among three different lots of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
- Trial name
- NCT00161811
- Testing
- Vero Cell-derived Influenza Vaccine, Egg cell-derived Influenza Vaccine
- Where
- 4 sites in Austria, Germany
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Multiple Myeloma (MM), CAR T Cells
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
This study investigates whether raising blood levels of beta-hydroxybutyrate (BHB) - a natural molecule produced by the body during fasting or a low-carbohydrate diet - is safe and feasible and can improve the effectiveness of…
- Conditions
- Multiple Myeloma (MM), CAR T Cells, Bispecific Antibodies
- Trial name
- BEAM-MM (NCT07564219)
- Testing
- Ketogenic diet, Ketogenic Drinks
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Secondary Immune Deficiency Disorder
Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig
Patients with chronic lymphocytic leukemia (CLL) are at increased risk of infections as compared to age matched controls, with infections being a major cause of morbidity and mortality.
- Trial name
- NCT03730129
- Testing
- Hizentra
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rochester General Hospital
Human Papilloma Virus, Anal Dysplasia
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen…
- Conditions
- Human Papilloma Virus, Anal Dysplasia, HIV
- Trial name
- PROTECT (NCT06624839)
- Testing
- Human papillomavirus (HPV) vaccine, 9-valent
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hepatitis B
Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders
Previous studies have shown that 5-10% of Hepatitis B Virus vaccine recipients produce none or to few antibodies after a standard immunization with 3 vaccines. These individuals are defined as non-responders.
- Trial name
- NCT01451801
- Testing
- Twinrix
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
COVID-19
Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine
The study describe 1 year durability of humoral and cellular immune responses in 150 individuals who received COVID-19 inactivated vaccine. all participants were recruited aged between 18 and 59 years old.
- Trial name
- NCT05072496
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Herpes Simplex, HIV Infections
An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies
To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients.
- Trial name
- NCT00002021
- Testing
- Foscarnet sodium
- Where
- 2 sites in United States
- Sponsor
- Astra USA
Non-hodgkin Lymphoma,B Cell, Vaccination Failure
Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma
The specific immune response to SARS-CoV-2 includes a humoral response - specific IgM appearing 5 days after the onset of symptoms while IgG appears after 14 days - and a T lymphocyte component, with specific activated CD8 and…
- Trial name
- LYMPHO-CoVac (NCT05050461)
- Testing
- Immunological analyses
- Where
- 7 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Versailles Hospital
Prostate Cancer
T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer
Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner. In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken…
- Trial name
- NCT01376674
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- University Hospital Tuebingen
Sarcoidosis, Sarcoidosis, Pulmonary
Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
Sarcoidosis is a multi-system granulomatous disorder that is triggered and influenced by gene-environment interactions. Although sarcoidosis predominantly affects the lungs in most cases, the clinical disease course is highly…
- Trial name
- NCT03145922
- Testing
- Observational Study
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Jewish Health
Melanoma
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
The incidence of melanoma is increasing with an estimated incidence of 59,940 cases and an annual death rate of 8110 in 2007. Although patients diagnosed with early stage disease have an excellent clinical outcome, patients…
- Trial name
- NCT01079741
- Testing
- NY-ESO-1 protein; Poly-ICLC; Montanide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Nina Bhardwaj
Immunity, Diarrhea
A Study on Immunological Effect of Vitamin A and Zinc in a Placebo Controlled 4 Cell Trial
Vitamin A deficiency in children is associated with increased mortality and morbidity due to respiratory tract and diarrhoeal infections.
- Conditions
- Immunity, Diarrhea, Respiratory Tract Infections
- Trial name
- NCT00374023
- Testing
- Zinc, or Vitamin A or both
- Where
- Bangladesh
- Volunteers
- 147 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh